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Copyright © 2008 AHC The aim of this study was to evaluate the immunohistochemical expression of MUC2,
MUC5AC, MUC6, and CD10 in ovarian mucinous adenoma (MA), mucinous borderline
tumor (MB), and mucinous adenocarcinoma (MC), and to analyze the relationship between
prognosis and these expressions. The expression of MUC2, MUC5AC, MUC6, and CD10
was evaluated by immunohistochemical analysis in 29 cases of MA, 29 cases of MB, and
26 cases of MC and scored based on the percentage of positive cells. Moreover, the ovarian
mucinous tumors were classified into 4 phenotypes based on the staining patterns: intesti-
nal, gastrointestinal, gastric, and unclassified patterns. The gastrointestinal pattern and the
expression of MUC2 and CD10 increased from MA to MC. Conversely, the gastric pattern
and MUC5AC expression decreased from MA to MC. Low MUC2 expression in MC was
correlated with a better long-term survival rate. MUC2 expression in MC may be a useful
predictor of the clinical outcome. The expression patterns of MUC2, MUC5AC, MUC6, and
CD10 indicated that intestinal metaplasia may arise from the gastric-like epithelium in
MA and that a close association exists between carcinogenesis and intestinal metaplasia in
major ovarian mucinous tumors.
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I. Introduction
Ovarian mucinous tumors are composed of mucin-
containing tumor cells and are classified into 3 types: muci-
nous adenoma (MA), mucinous borderline tumor (MB),
and mucinous adenocarcinoma (MC) [16]. According to
the current classification of the World Health Organization
(WHO), MB is further classified into 2 types: the intestinal
type (MBI) and endocervical-like (MBE) [16]. The former
is mainly composed of intestinal-like epithelium that usually
contains goblet cells, whereas the latter is mainly composed
of tumor cells resembling endocervical columnar epithe-
lium.
Mucins are high-molecular-weight glycoproteins con-
taining oligosaccharides that are attached to an apomucin
protein backbone via O-glycosidic linkages, and are synthe-
sized in the glandular epithelium [1, 12, 17]. Mucins are
classified into cell surface-associated mucin and gel-form-
ing mucin [12, 20, 30]. MUC2, MUC5AC, and MUC6
represent gel-forming mucin, and are expressed in several
secretory epithelia. CD10 was initially identified as the
common acute leukemia antigen (CALLA) [15] and is
widely expressed in epithelial and non-epithelial tissues.
Many studies have evaluated the combined expression
patterns of MUC2, MUC5AC, MUC6, CD10, human gastricHirabayashi et al. 16
mucin, and M-GGMC-1 in the non-neoplastic or neoplastic
epithelium of the stomach, gallbladder, intrahepatic biliary
system, and Barrett’s esophagus [5, 18, 19, 22, 23, 29, 32–
34, 38, 40–42]. The gastric epithelium is usually positive for
MUC5AC (gastric foveolar epithelium) and MUC6 (gastric
pyloric gland) but negative for MUC2 [27, 39]. On the other
hand, the goblet cells of the intestinal epithelium are gener-
ally positive for MUC2 but negative for MUC5AC and
MUC6 [1, 2, 39]. The brush border of the small intestinal
epithelium is positive for CD10 [37]. The expression pattern
of MUC2, MUC5AC, MUC6, and CD10 in the endocer-
vical glandular epithelium is similar to that in the gastric
epithelium [3, 4, 13, 21, 28, 43].
Some studies in the literature have reported the expres-
sion of mucins in ovarian tumors [1, 8, 10, 11, 14, 20, 35].
However, determination of the phenotype based on the
expression patterns of MUC2, MUC5AC, MUC6, and
CD10 in ovarian mucinous tumors has not been well docu-
mented. Therefore, we evaluated the phenotype based on
the immunohistochemical expression patterns of MUC2,
MUC5AC, MUC6, and CD10 in ovarian mucinous tumors
to determine whether a relationship exists between the ex-
pressions of MUC2, MUC5AC, MUC6, and CD10 and the
prognosis of MC.
II. Materials and Methods
Tumor specimens
In this study, ovarian mucinous tumors surgically re-
sected at the Tokai University Hospital between 1991 and
2006 were used. All tumors were classified according to the
WHO classification [16]. The number and histological type
of ovarian tumors were as follows: 29, MA; 29, MB; and 26,
MC. There were 18 cases of MBI and 11 cases of MBE. The
mean age of the MA patients was 39.1±2.8 years (range,
16–69 years) and that of MC patients was 47.8±3.0 years
(range, 18–82 years). The mean age of the MB patients was
39.2±2.4 years (range, 18–72 years): MBI, 42.2±3.0 years
(range, 24–72 years) and MBE, 34.4±3.8 years (range, 18–
65 years). Ovarian cancer was classified into various stages
according to the International Federation of Gynecology and
Obstetrics (FIGO) classification [36]. The number of cases
of each stage was as follows: stage I, 16 cases; stage II, 0
cases; stage III, 6 cases; and stage IV, 4 cases.
Immunohistochemical analysis
One representative section was selected for immuno-
histochemical staining based on the histological findings of
the ovarian mucinous tumors. Each tissue was formalin-
fixed, paraffin-embedded, and cut into 4-µm-thick sections.
The sections were deparaffinized in xylene and rehydrated
through a graded ethanol series to distilled water. The
monoclonal antibodies used were MUC2 (clone Ccp58,
dilution 1:100; Novocastra, Newcastle-upon-Tyne, UK),
MUC5AC (clone CLH2, dilution 1:100; Novocastra), MUC6
(clone CLH5, dilution 1:100; Novocastra), and CD10 (clone
56C6, dilution 1:50; Novocastra). For antigen retrieval,
each slide was boiled in citrate buffer (MUC2, MUC5AC,
and MUC6, pH 6.0; CD10, pH 7.0) in a pressure cooker for
10 min. An automated immunostainer (Dako autostainer;
Dako Japan Co. Ltd., Tokyo, Japan) was utilized for
immunohistochemical staining. The antibodies were de-
tected using the EnVision system (Dako Japan Co. Ltd.)
with 3,3'-diaminobenzidine as the chromogen. Appropriate
positive and negative tissue control samples were used.
Evaluation of immunohistochemical staining
Each staining was evaluated based on the proportion of
positive cells as follows: 0, (negative); 1+, (less than 5%);
2+, (6–25%); 3+, (26–50%); 4+, (51–75%); and 5+, (76–
100%). In addition, ovarian mucinous tumors were classi-
fied into the following 4 phenotypes based on the staining
patterns of MUC2, MUC5AC, MUC6, and CD10: intestinal
pattern (MUC2 and/or CD10: score 1+ to 5+ and MUC5AC
and MUC6: score 0), gastrointestinal pattern (MUC2 and/or
CD10: score 1+ to 5+ and MUC5AC and/or MUC6: score
1+ to 5+), gastric pattern (MUC2 and CD10: score 0 and
MUC5AC and/or MUC6: score 1+ to 5+), and unclassified
pattern (MUC2 and CD10: score 0 and MUC5AC and
MUC6: score 0) (Fig. 1).
Statistical analysis
The data were analysed using the Tukey-Kramer test,
paired t test, and Kruskal Wallis test. Survival distributions
were estimated by Kaplan-Meier analysis. The log-rank test
was performed to compare the survival times in MC accord-
ing to the expression scores of MUC2, MUC5AC, MUC6,
and CD10 and the 4 phenotypic patterns. P<0.05 was inter-
preted as significant. Statistical calculations were performed
using SPSS 15.0J (SPSS Japan, Tokyo, Japan).
Fig. 1. Four phenotypes based on the expression of MUC2, MUC5AC, MUC6, and CD10.Mucin Expression in Ovarian Tumors 17
III. Results
Expression of MUCs and CD10 in ovarian mucinous tumors 
(Table 1 and Fig. 2)
MUC2
The proportion of MUC2-positive cells increased from
MA and MB to MC. MC exhibited a higher proportion of
MUC2-positive cells than MA (P=0.04); however, there was
no significant difference in the proportion of MUC2-positive
cells between MA and MB or between MB and MC. Goblet
cells were mainly MUC2 positive; however, the proportion
of MUC2-positive goblet cells was lower than that of the
hematoxylin and eosin (H&E)-stained goblet cells.
MUC5AC
All cases of MA and MB were positive for MUC5AC,
but MUC5AC expression in MC was significantly lower
than that in MA and MB (P<0.001). MUC5AC was ex-
pressed in the cytoplasm of endocervical-like tumor cells.
Furthermore, MUC5AC was also expressed in the cyto-
plasm of both MUC2-positive and MUC2-negative goblet
cells. Mucinous tumors exhibiting a diffuse positive reaction
for MUC2 were simultaneously positive for MUC5AC.
Fig. 2. Expression of MUC2, MUC5AC, MUC6, and CD10 in mucinous adenoma (MA), mucinous borderline tumor (MB), and mucinous
adenocarcinoma (MC).Hirabayashi et al. 18
MUC6
MUC6 was expressed in the cytoplasm of endocervi-
cal-like tumor cells. The MUC6 score was very low in each
histological type. There was no significant difference in the
proportion of MUC6-positive cells among MA, MB, and
MC.
CD10
The proportion of CD10-positive cells increased from
MA and MB to MC (P=0.008). CD10 was mainly expressed
in the apical membrane of the goblet cells or in tumor cells
near the goblet cells. CD10 was expressed in both MUC2-
positive and MUC2-negative tumor cells.
Expression of MUCs and CD10 in MB (Table 2)
MUC2 was expressed more strongly in MBI than in
MBE (P<0.001). The expression of CD10 was higher in
MBI than that in MBE; however, there was no significant
difference in the expression of MUC5AC, MUC6, and
CD10 between MBE and MBI. MUC5AC was diffusely ex-
pressed in both MBE and MBI.
Phenotypes based on the expression patterns of MUC2, 
MUC5AC, MUC6, and CD10 (Tables 3 and 4)
The gastrointestinal pattern increased from MA and
MB to MC (P=0.002). On the other hand, the gastric pattern
decreased from MA and MB to MC (P<0.001). The intesti-
nal pattern was not observed in any histological type. The
unclassified pattern was identified only in MC (3 cases,
11.5%) (P=0.032). Of the MB cases, 90.9% of the MBE
cases demonstrated the gastric pattern and 83.3% of the
MBI cases, the gastrointestinal pattern. No case of MBE or
MBI exhibited the intestinal pattern or unclassified pattern.
Correlation with patient survival
In MC, the low score, 0 to 2+, for MUC2 (n=22) was
associated with a better long-term survival rate (P=0.025)
(Fig. 3). In MC, no significant difference was observed in
the survival rates among the expressions of MUC5AC,
MUC6, and CD10 or among the intestinal, gastrointestinal,
unclassified, and gastric patterns. No relationship was ob-
served between the FIGO stage and the expression of MUCs
and CD10 or the 4 phenotypic patterns.
IV. Discussion
The present study demonstrated that the gastrointesti-
nal pattern increased but the gastric pattern decreased from
MA to MC. The intestinal pattern was not observed in the
mucinous tumors. The unclassified pattern was identified
only in MC. In the MB cases, MBI and MBE were com-
paratively correlated with the gastrointestinal and gastric
patterns, respectively.
The expression of the intestinal markers MUC2 and
CD10 increased from MA and MB to MC. Previous studies
in the literature also present similar data demonstrating that
MUC2 expression increased concomitantly with the transi-
tion from MA to MC [1, 10, 11, 35]. Although Dong et al.
[10] reported that no relationship existed between MUC2
expression and the prognostic data related to clear cell
adenocarcinoma, endometrioid adenocarcinoma, mucinous
adenocarcinoma, serous adenocarcinoma, and mixed meso-
dermal tumor of the ovary, our results demonstrated that
MC with a strong positive reaction for MUC2 was associ-
ated with a poor prognosis; however, no relationship was
observed between CD10 expression and prognosis. In
MC, the poor prognosis with a strong positive reaction for
MUC2 might be related to the increase in MUC2 expres-
sion from MA to MC. Focusing on the relationship between
MUC2 and p53, Ookawa et al. [24] suggested that MUC2
gene is activated by p53 in many cell types. Shimonishi et al.
[31] reported that both MUC2 and p53 were expressed more
frequently in intraductal papillary neoplasia of the liver than
in nonneoplastic bile ducts. p53 may be a important role for
MUC2 expression in the ovarian mucinous tumor.
The gastric marker MUC5AC demonstrated high




MA (n=29) MB (n=29) MC (n=26) Pairwise P-value
Overall P-value
(mean score±SE) MA vs. MB MA vs. MC MB vs. MC
MUC2 0.4±0.2 0.9±0.2 1.2±0.3 0.231 0.04 0.66 0.046
MUC5AC 4.6±0.2 4.5±0.2 2.4±0.4 0.913 <0.001 <0.001 <0.001
MUC6 0.8±0.2 0.3±0.1 0.7±0.2 0.104 0.993 0.148 0.077
CD10 0.1±0.1 0.2±0.1 0.8±0.3 0.792 0.008 0.46 0.008
Table 2. Comparison of MUC2, MUC5AC, MUC6, and CD10
expression in mucinous borderline tumor of endocervical-




MBE (n=11) MBI (n=18)
P-value
(mean score±SE)
MUC2 0 1.5±0.3 <0.001
MUC5AC 4.2±0.4 4.6±0.2 0.262
MUC6 0.3±0.2 0.3±0.1 0.983
CD10 0.1±0.1 0.3±0.1 0.158Mucin Expression in Ovarian Tumors 19
Table 3. Mucinous adenoma (MA), mucinous borderline tumor (MB), and mucinous adenocarcinoma (MC) classified into intestinal, gastro-
intestinal, gastric, and unclassified patterns based on the staining patterns of MUC2, MUC5AC, MUC6, and CD10
MA (n=29) MB (n=29) MC (n=26)
P-value
n (%) n (%) n (%)
Gastrointestinal pattern
MUC2(+)/MUC5AC(+)/MUC6(−)/CD10(−) 2 (6.9) 8 (27.6) 4 (15.4)
MUC2(+)/MUC5AC(+)/MUC6(+)/CD10(−) 1 (3.4) 3 (10.3) 3 (11.5)
MUC2(+)/MUC5AC(+)/MUC6(+)/CD10(+) 3 (10.3) 1 (3.4) 5 (19.2)
MUC2(+)/MUC5AC(+)/MUC6(−)/CD10(+)0 ( 0 ) 4 ( 1 3 . 8 ) 3 ( 1 1 . 5 )
MUC2(−)/MUC5AC(+)/MUC6(+)/CD10(+) 0 (0) 0 (0) 1 (3.8)
MUC2(−)/MUC5AC(+)/MUC6(−)/CD10(+) 0 (0) 1 (3.4) 0 (0)
MUC2(−)/MUC5AC(−)/MUC6(+)/CD10(+) 0 (0) 0 (0) 1 (3.8)
Total 6 (20.7) 17 (58.6) 17 (65.4) 0.002
Gastric pattern
MUC2(−)/MUC5AC(+)/MUC6(−)/CD10(−) 12 (41.4) 10 (34.5) 5 (19.2)
MUC2(−)/MUC5AC(+)/MUC6(+)/CD10(−) 11 (37.9) 2 (6.9) 1 (3.8)
MUC2(−)/MUC5AC(−)/MUC6(+)/CD10(−) 0 (0) 0 (0) 0 (0)
Total 23 (79.3) 12 (41.4) 6 (23.1) <0.001
Unclassified pattern
MUC2(−)/MUC5AC(−)/MUC6(−)/CD10(−) 0 (0) 0 (0) 3 (11.5) 0.032
Table 4. Mucinous borderline tumor of endocervical-like (MBE) and mucinous borderline tumor of the intestinal type (MBI) were classified into
intestinal, gastrointestinal, gastric, and unclassified patterns based on the staining patterns of MUC2, MUC5AC, MUC6, and CD10
MBE (n=11) MBI (n=18)
P-value
n( % ) n( % )
Gastrointestinal pattern
MUC2(+)/MUC5AC(+)/MUC6(−)/CD10(−) 0 (0) 8 (44.4)
MUC2(+)/MUC5AC(+)/MUC6(+)/CD10(−) 0 (0) 3 (16.7)
MUC2(+)/MUC5AC(+)/MUC6(+)/CD10(+) 0 (0) 1 (5.6)
MUC2(+)/MUC5AC(+)/MUC6(−)/CD10(+) 0 (0) 3 (16.7)
MUC2(−)/MUC5AC(+)/MUC6(+)/CD10(+) 0 (0) 0 (0)
MUC2(−)/MUC5AC(+)/MUC6(−)/CD10(+) 1 (9.1) 0 (0)
MUC2(−)/MUC5AC(−)/MUC6(+)/CD10(+) 0 (0) 0 (0)
Total 1 (9.1) 15 (83.3) <0.001
Gastric pattern
MUC2(−)/MUC5AC(+)/MUC6(−)/CD10(−) 8 (72.7) 3 (16.7)
MUC2(−)/MUC5AC(+)/MUC6(+)/CD10(−) 2 (18.2) 0 (0)
MUC2(−)/MUC5AC(−)/MUC6(+)/CD10(−) 0 (0) 0 (0)
Total 10 (90.9) 3 (16.7) <0.001
Unclassified pattern
MUC2(−)/MUC5AC(−)/MUC6(−)/CD10(−) 0 (0) 0 (0) 1.000
Fig. 3. Overall survival in MC cases according to the MUC2 score.
A better long-term survival rate was noted for MC cases with a
score of 0 to 2+.Hirabayashi et al. 20
scores for both MA and MB. On the other hand, the expres-
sion of MUC5AC decreased in MC. These results are similar
to those of previous studies [1]. Based on our observations,
it appears that no relationship exists between MUC5AC
expression and prognosis in ovarian carcinomas. The other
gastric marker MUC6 demonstrated very low scores in
MA, MB, and MC in contrast to those demonstrated by
MUC5AC. There was no significant increase or decrease in
MUC6 expression from MA to MC, as observed for the
other markers.
Interestingly, the expression patterns of MUC2 and
MUC5AC in the ovarian mucinous tumors are similar to
those in the endocervical glandular epithelium of the uterine
cervix. Although the normal endocervical mucosa of the
uterine cervix is usually positive for MUC5AC but negative
for MUC2, MUC2 is expressed in endocervical adenocarci-
noma; further, MUC5AC expression is lower in endocervi-
cal adenocarcinoma than in the normal endocervical mucosa
[4, 28, 43]. It is possible that carcinogenesis in ovarian
mucinous and endocervical adenocarcinomas is similar
with regard to MUC expression.
Focusing on the immunohistochemical expression in
the goblet cells of the ovarian mucinous tumor, most of these
cells were MUC2 positive/MUC5AC positive or MUC2
negative/MUC5AC positive in contrast to the intestinal gob-
let cells that were MUC2 positive and MUC5AC negative
[39]. These findings revealed that most of the goblet cells
identified upon H&E staining of the ovarian mucinous
tumors were immature for mucin expression.
The abovementioned results suggest that MUC5AC is
the basic mucin present in ovarian mucinous tumors and that
intestinal metaplasia is accentuated from MA to MC. The lo-
cation of MUC2 and MUC5AC on the same chromosome
(11p15.5) may be related to the observation of intestinal
metaplasia in ovarian mucinous tumors [1, 9]. Ovarian car-
cinoma may develop de novo or arise from a pre-existing
benign epithelium [6, 7, 25, 26]. The increase in the
gastrointestinal pattern from MA to MC may suggest that
carcinogenesis originated from the intestinal metaplasia in
MA and MB. Otherwise, the presence of the gastric pattern
in MB and MC may suggest the presence of other carcino-
genesis pathways that are unrelated to intestinal metaplasia.
In conclusion, the results of our study revealed 4 phenotypes
based on the expression patterns of MUC2, MUC5AC,
MUC6, and CD10 among MA, MB, and MC. The gastro-
intestinal pattern increased from MA to MC. In contrast,
the gastric pattern decreased from MA and MB to MC. In
addition, the low expression of MUC2 in MC was associated
with a better prognosis. These results suggested that the
difference in MUC2 expression among MC cases may be
useful in predicting the clinical outcome. Furthermore, the
results indicated that intestinal metaplasia may arise from
the gastric-like epithelium in MA and that carcinogenesis is
probably related to intestinal metaplasia. On the other hand,
the presence of the gastric pattern suggests the possibility of
carcinogenesis unrelated to intestinal metaplasia.
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